Mediwound Ltd (MDWD) 수입

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. ; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.